To include your compound in the COVID-19 Resource Center, submit it here.

Zavante's Zolyd meets in pivotal cUTI study

Zavante Therapeutics Inc. (San Diego, Calif.) said Zolyd fosfomycin (ZTI-01) met the primary endpoint in the Phase II/III ZEUS trial

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE